5-25-06

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Julian Nikolchev	)	
		)	Group Art Unit: 3743
Serial No.:	10/600,298	)	Examiner: Henry Bennett
		)	
Filed:	June 20, 2003	)	

For: Contraceptive Transcervical Fallopian Tube Occlusion Devices and Methods

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Certificate of Mailing by "Express Mail"

Express Mail Label No. **EV 787441382US** Date of Deposit: **May 24, 2006**

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Signature: Scarlett Pereida

Applicants' Summary of the Interview of May 3, 2006

Dear Sir:

Applicants wish to thank SPRE Jessica Harrison for the courtesies extended during the telephonic interview conducted on May 3, 2006 with Applicants' representative James Conley.

The Examiner and Applicants' representative discussed the Office Action mailed April 21, 2006 and general interference practice. The Examiner informed Applicants' representative that a discussion with SPE Herny Bennett revealed that the April 21, 2006 Office Action was inconsistent with the Office position and would therefore be vacated. Examiner Harrison informed Applicants' representative that because the Office Action was vacated, Applicants were relieved of the duty to respond to the 30 day deadline set in that Action and that a new deadline to respond would be set in a forthcoming replacement Action. Both the Office and Applicants' representative agreed to work together

expeditiously to resolve all outstanding issues and to place the application in condition for consideration of the request for interference.

For the Examiners' convenience, family trees of the applications and patents relevant to the interference are attached to this communication along with a copy of Applicants' 1995 application 08/475,252.

Respectfully submitted,

James P. Conley
Reg. No. 52,459

BAKER & McKENZIE
2001 Ross Avenue
Dallas, Texas 75201
(858) 523-6232 (telephone)
(214) 978-3099 (facsimile)

5/24/06
Date

Conceptus Application Family Tree

1993 · 1994 · 1995 · 1996 · 1997 · 1998 · 1999 · 2000 · 2001 · 2002 · 2003 · 2004 · 2005 · 2006

08/474,779
6/7/1995

08/475,252
6/7/1995

60/058,861
9/24/1997
(provisional)

(fully supports 835 app--has the exact same spec and drawings)

CIP

abandoned
6/19/1998

CIP

08/083,835
6/6/1998

CON

09/322,638
5/28/1999

CIP

09/324,078
6/1/1999

CON

09/591,874
6/12/2000

CON

09/592,123
6/12/2000

#######
6,145,505

1/23/2001
6,178,240

CON

09/912,067
7/23/2001

C[redacted]s
fr[redacted]ent

CON

10/113,109
3/28/2002

publication
2/21/2002
2002/0020417

C[redacted]s
f[redacted]p

publication
8/1/2002
2002/0100480

3/4/2003
6,526,979

CON

10/600,298
6/20/2003

CON

10/641,333
8/13/2003

C[redacted]s
fr[redacted]ent

#######
6,634,351

1/20/2004
6,679,266

CON

10/779,541
2/12/2004

C[redacted]s
f[redacted]p

CON

10/785,855
2/23/2004

2/3/2004
6,684,834

C[redacted]s
fr[redacted]ent

C[redacted]s
f[redacted]p

publication
4/29/2004
2004/0079377

publication
7/1/2004
2004/0127918

3/16/2004
6,705,323

CON

10/845,645
5/14/2004

CON

10/846,047
5/14/2004

3/29/2005
6,871,650

11/106,804
4/15/2005

Office Action

Office Action

Response

Office Action

Response

Office Action

Response

Office Action

Restriction

Office Action

Response

abandoned

not yet docketed

Examiner= Mike Brown

Restriction
Examiner= Mike Brown

Examiner= Mike Brown

Examiner= Mike Brown

Office Action
Vacated
Examiner= Bennett

11/367,871
3/2/2006

C[redacted]s
f[redacted]p

doc# 96533

Ovion Application Family Tree

1998

08/770,123
12/18/1998

09/112,085
7/8/1998

1999

CIP — CON

09/468,749
12/21/1999

2000

[redacted]p

8/1/2000
6,096,052

2001

CON

09/911,551
7/23/2001

publication
11/15/2001
2001/0041900

[redacted]p

2002

publication
1/31/2002
2002/0013589

publication
3/7/2002
2002/0029051

8/13/2002
6,432,116

CON

10/272,840
10/16/2002

2003

publication
2/13/2003
2003/0029457

60/483,587
6/27/2003

2004

[redacted]p

[redacted]p — CIP — provisional

10/880,355
6/28/2004

CON

10/972,857
10/25/2004

2005

publication
4/21/2005
2005/0081862

publication
3/3/2005
2005/0045183

CON

11/116,480
4/8/2005

Restriction

Office Action

Response

publication
10/6/2005
2005/021768(

Response

abandoned

Office Action

Response

2006

Office Action

[redacted]p

Response

Issue Fee Paid

Election Filed

Examiner=
Mike Brown

Examiner=
Bennett

Examiner=
Lopez

Examiner=
Julian Woo

not yet
docketed

docll 98483

PATENT APPLICATION SERIAL NO. 08/475252

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

260 YC 20-1430 07/03/95 08475252
26057 201 506.00CH 16355-002500

PTO-1556
(5/87)

BAR CODE LABEL

U.S. PATENT APPLICATION

SERIAL NUMBER	FILING DATE	CLASS	GROUP ART UNIT
08/475,252	06/07/95	128	3301

APPLICANT

JULIAN NIKOLCHEV, PORTOLA VALLEY, CA; DAI TON, SAN JOSE, CA.

CONTINUING DATA********
VERIFIED

_____

FOREIGN/PCT APPLICATIONS********
VERIFIED

_____

FOREIGN FILING LICENSE GRANTED 08/01/95 ***** SMALL ENTITY *****

STATE OR COUNTRY	SHEETS DRAWING	TOTAL CLAIMS	INDEPENDENT CLAIMS	FILING FEE RECEIVED	ATTORNEY DOCKET NO.
CA	5	35	5	$606.00	16355-002500

ADDRESS

TOWNSEND AND TOWNSEND KHOURIE AND CREW
STEUART STREET TOWER
ONE MARKET PLAZA
SAN FRANCISCO CA 94105

TITLE

CONTRACEPTIVE TRANSCERVICAL FALLOPIAN TUBE OCCLUSION DEVICES HAVING MECHANICAL FALLOPIAN TUBE ATTACHMENT

This is to certify that annexed hereto is a true copy from the records of the United States Patent and Trademark Office of the application which is identified above.

By authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

Date Certifying Officer

TOWNSEND and TOWNSEND KHOURIE and CREW
Steuart Street Tower
One Market Plaza
San Francisco, CA 94105
(415) 543-9600

08/475252

Atty. Docket No. 355-002500

"Express Mail" Label No. TB 175027358 US

Date of Deposit June 7, 1995

PATENT APPLICATION
COMMISSIONER OF PATENT AND TRADEMARKS
Washington, D. C. 20231

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D. C. 20231

By _____

Sir:

Transmitted herewith for filing is the [X] patent application, [ ] continuation-in-part patent application of

Inventors: **JULIAN NIKOLCHEV and DAI TON**

For: **CONTRACEPTIVE TRANSCERVICAL FALLOPIAN TUBE OCCLUSION DEVICES HAVING MECHANICAL FALLOPIAN TUBE ATTACHMENT**

Enclosed are:

[X] Five sheet(s) of [ ] formal [X] informal drawing(s).

[X] An assignment of the invention to Conceptus, Inc., a California corporation.

[ ] A [ ] signed [ ] unsigned Declaration & Power of Attorney.

[X] A [X] signed [ ] unsigned Declaration.

[X] A Power of Attorney by Assignee with Certificate Under 37 C.F.R. Section 3.73(b).

[X] A verified statement to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27.

[ ] A certified copy of a _____ application.

[ ] Information Disclosure Statement under 37 CFR 1.97.

[ ] Enclosed is a petition to extend time to respond in the parent application of the continuation-in-part application.

[ ]

The filing fee has been calculated as shown below:

	(Col. 1)	(Col. 2)	SMALL ENTITY			OTHER THAN A SMALL ENTITY	
FOR:	NO. FILED	NO. EXTRA	RATE	FEE	OR	RATE	FEE
BASIC FEE				$ 365	OR		$730
TOTAL CLAIMS	35 -20=	* 15	15 x11=	$ 165	OR	x22=	$
INDEP CLAIMS	5 -3=	* 2	2 x38=	$ 76	OR	x76=	$
[ ] MULTIPLE DEPENDENT CLAIM PRESENTED			+120=	$ --	OR	+240=	$
			TOTAL	$ 606	OR	TOTAL	$

* If the difference in Col. 1 is less than zero, enter "0" in Col. 2

Please charge Deposit Account No. 20-1430 as follows:

[X] Filing fee $ 606.00

[X] Any additional fees associated with this paper or during the pendency of this application

[ ] The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b).

[ ] A check for $_____ is enclosed.

A duplicate of this sheet is enclosed.

Respectfully submitted,
TOWNSEND and TOWNSEND KHOURIE and CREW

_____
Mark D. Barrish
Reg. No. 36,443
Attorneys for Applicant

Telephone:
(415) 543-9600

J:\16355\25APP.TRN

Attorney Docket No. 16355-25
Client Reference No. 95003-1

PATENT APPLICATION

CONTRACEPTIVE TRANSCERVICAL FALLOPIAN TUBE OCCLUSION DEVICES HAVING MECHANICAL FALLOPIAN TUBE ATTACHMENT

Inventors:

Julian Nikolchev, a citizen of
The United States, residing at
251 Durazno Way,
Portola Valley, California, 94028;

Dai Ton, a citizen of
The United States, residing at
1693 Flickinger Avenue
San Jose, California, 95131; and

Assignee:

CONCEPTUS, INC.
1021 Howard Avenue
San Carlos, California 94070,
a California corporation.

Status:

SMALL ENTITY

TOWNSEND and TOWNSEND KHOURIE and CREW
Steuart Street Tower, 20th Floor
One Market Plaza
San Francisco, California 94105
(415) 326-2400

(5)

08/475252 A

PATENT

Attorney Docket No. 16355-25

CONTRACEPTIVE TRANSCERVICAL FALLOPIAN TUBE OCCLUSION DEVICES HAVING MECHANICAL FALLOPIAN TUBE ATTACHMENT

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates generally to contraception, and more particularly to intrafallopian contraceptive devices and nonsurgical methods for their delivery.

Worldwide demand exists for safe, effective methods of both contraception and permanent sterilization. Although a variety of contraception and sterilization methods are available, all of the existing methods have limitations and disadvantages. Thus, the need for additional safe, low cost, reliable methods of contraception and permanent sterilization, both in developed and less developed countries, is widely recognized.

Many presently available contraception methods require significant user involvement, and user non-compliance results in quite high rates of failure. While the theoretical effectiveness of existing contraceptives, including barrier methods and hormonal therapies, is well established, overcoming user noncompliance to improve overall efficacy has proven difficult.

One form of contraception which is less susceptible to user noncompliance is the intrauterine device (IUD). IUDs have been found to have higher rates of reliability, and are effective for a longer period of time, than most other commercially available contraceptives. Unfortunately, IUDs are also associated with serious infectious complications. For this reason, the use of IUDs within the United States has decreased dramatically. Additionally, IUDs are subject to unplanned expulsion, and must be removed due to excessive pain or bleeding in a percentage of cases, further reducing the

acceptance of the IUD as a contraceptive method. Interestingly, the efficacy of copper IUDs appears to be higher than that of non-metallic IUDs. The reason for this has not been fully explained.

Commercially available options for permanent sterilization include fallopian tube ligation and vasectomy. These methods are surgical, are difficult to reverse, and are not available to many people in the world. It is common knowledge that fertilization occurs in the fallopian tubes where the sperm and ovum meet. Tubal ligation avoids this by complete occlusion of the fallopian tubes.

It has previously been proposed to reversibly occlude the fallopian tubes, for example, by *in vitro* formation of an elastomeric plug, or otherwise anchoring a device on either side of the narrowest region of fallopian tube, called the "isthmus." Such fallopian tube occlusion methods appear promising; however, an unacceptably high percentage of the non-surgical devices proposed to date have become dislodged during previous studies. Even where non-surgical intrafallopian devices have remained in place, they have been found to be only moderately effective at preventing conception.

For these reasons, it would be desirable to provide effective, reliable intrafallopian devices for contraception and sterilization. It would be particularly desirable to provide highly effective intrafallopian devices which did not require surgery for placement. It would be especially desirable if such devices and methods allowed easy placement of the device, but were less susceptible to being dislodged than previously proposed non-surgical intrafallopian devices.

2. Description of the Related Art

The experimental use of a stainless steel intrafallopian device is described in *Transcatheter Tubal Sterilization in Rabbits*, Penny L. Ross, RT 29 "Investigative Radiology", pp. 570-573 (1994). The experimental use of an electrolytically pure copper wire as a surgical contraceptive intrafallopian device in rats was described in "Antifertility

Effect of an Intrafallopian Tubal Copper Device", D.N. Gupta, 14 *Indian Journal of Experimental Biology*, pp. 316-319 (May 1976).

U.K. Patent Application Pub. No. 2,211,095 describes a uterine screw plug for blocking the fallopian tube. European Patent Application Pub. No. 0,010,812 describes a device for placement in the oviducts having enlargements at either end for anchoring the device. The same device appears to be described in Netherlands Patent No. 7,810,696.

The use of tubal occlusion devices is described in "Hysteroscopic Oviduct Blocking With Formed-in-Place Silicone Rubber Plugs", Robert A. Erb, Ph.D., et al., *The Journal of Reproductive Medicine*, pp. 65-68 (August 1979). A formed-in-place elastomeric tubal occlusion device is described in U.S. Patent No. 3,805,767, issued to Erb. U.S. Patent No. 5,065,751, issued to Wolf, describes a method and apparatus for reversibly occluding a biological tube. U.S. Patent No. 4,612,924, issued to Cimber, describes an intrauterine contraceptive device which seals the mouths of the fallopian tubes.

German Patent No. 28 03 685, issued to Brundin, describes a device for plugging a body duct with a device which swells when in contact with a body fluid.

Alternative contraceptive devices are disclosed in copending U.S. Patent Application Serial No. 08/474,779 ~~(attorney docket no. 16355-24)~~, the full disclosure of which is herein incorporated by reference.

SUMMARY OF THE INVENTION

The present invention provides intrafallopian devices and methods for their placement to prevent conception. The intrafallopian devices of the present invention are transcevically delivered and mechanically anchored within the fallopian tube to provide long term contraception, or alternatively permanent sterilization, without the need for surgical procedures or the risks of increased bleeding, pain, and infection associated with intrauterine devices (IUDs).

The intrafallopian devices of the present invention generally comprise a structure having a lumen-traversing region with a helical outer surface. The helical surface is mechanically anchored by a resilient portion of the structure which is biased to form an enlarged secondary shape, preferably forming distal and proximal anchoring loops. The anchoring loops help prevent the helical outer surface from rotating out of position, and also directly deter axial motion within the fallopian tube.

The use of copper in the intrafallopian device of the present invention improves its efficacy as a contraceptive method. Devices formed from plastically deformable materials, however, are less readily restrained in the fallopian tube. Apparently, the large variation in the actual shape and dimensions of fallopian tubes does not provide reliable anchoring for a pre-formed deformable intrafallopian device. The intrafallopian device of the present invention therefore comprises a resilient structure, usually a metallic coil, which includes a copper alloy or plating, ideally comprising an alloy including at least 75% copper. The coil material typically includes beryllium, zinc, stainless steel, platinum, a shape memory alloy, such as Nitinol™, or the like. Preferably, the coil is composed of an alloy of beryllium and copper. Although the present device will generally result in occlusion, it need not completely occlude the fallopian tube to prevent the meeting of the sperm and ovum. Instead, the presence of the copper on the resilient structure is sufficient to provide effective contraception.

Conveniently, the present invention further comprises non-surgical placement of such intrafallopian devices by transcervical introduction. The resilient structure is restrainable in a straight configuration, e.g., by use of a corewire, greatly facilitating and reducing the risks of introduction. Thus, the cost and dangers associated with existing surgical contraceptive and sterilization procedures are avoided.

In a first aspect, a contraceptive intrafallopian device according to the present invention comprises a proximal anchor, a distal anchor, and a lumen-traversing region extending between the anchors. The lumen traversing region has a helical outer surface and a cross-section which is smaller than the cross-sections of the proximal and distal anchors.

Preferably, the lumen-traversing region comprises a resilient structure, generally having a ribbon wound over the outer surface to form the helical shape. Anchoring is enhanced by a sharp outer edge on the ribbon. As described above, at least one of the proximal anchor, the distal anchor, and the lumen-traversing region preferably comprises copper. The proximal and distal anchors generally comprise a resilient structure biased to form an enlarged secondary shape, thereby allowing the device to be restrained in a straight configuration to facilitate transcervical introduction.

In another aspect, a contraceptive intrafallopian device according to the present invention comprises a primary coil having a proximal loop, a distal loop, and an intermediate straight section between the loops. A helical ribbon is wound over at least a portion of the intermediate section, forming a helical surface to mechanically anchor the device within the fallopian tube.

The ribbon of the present intrafallopian device generally protrudes sufficiently to firmly engage the tubal wall. Preferably, the ribbon has a width in the range between .005 and .1 inch, a thickness in the range between .001 and .2 inch, and a pitch in the range between .01 and .2 inch. The overall device geometry preferably facilitates introduction and retention, but is not large or rigid enough to interfere with internal tissue movements. Usually, the device has a length in the range between 1.5 cm and 7.5 cm when in a relaxed state, while the distal loop and the proximal loop have outer diameters of at least 3 mm. Preferably, the primary coil has an outer diameter in the range between .2 mm and 5 mm.

In another aspect, a system for delivering intrafallopian contraceptive devices according to the present invention comprises a primary coil having a proximal loop, a distal loop, and an intermediate straight section between the loops. Additionally, a lumen extends from a proximal end of the proximal loop to near a distal end of the distal loop. A helical ribbon is wound over at least a portion of the intermediate section, forming a helical surface to mechanically anchor the device within the fallopian tube. A corewire is removably disposed within the lumen of the primary coil. The corewire restrains the primary coil in a straight configuration, facilitating trancervical introduction. Optionally, the corewire is threadably received by the primary coil. Alternatively, a release catheter is slidably disposed over the corewire proximally of the primary coil to restrain the primary coil while the corewire is withdrawn proximally from the fallopian tube.

The helical ribbon is anchored in the fallopian tube by the distal and proximal loops. The ribbon is set in the tubal wall while the device is restrained in a straight configuration over a corewire by torquing on the corewire. Withdrawing of the corewire then releases the anchors. The distal anchor is generally inserted into the ampulla, distal of the isthmus, while the proximal anchor is located in the ostium. These anchors prevent rotation of the device, and also help avoid axial movement.

In yet another aspect, an intrafallopian contraceptive method according to the principles of the present invention comprises restraining a resilient contraceptive structure in a straight configuration over a corewire, where the resilient structure includes a lumen-traversing region having a helical outer surface. The resilient structure is transcervically introduced into a target region of a fallopian tube, typically in the region of the ostium, and the corewire is withdrawn from the resilient structure. The resilient structure is mechanically anchored within the fallopian tube, a portion of the resilient structure assuming an enlarged secondary shape which is larger

in cross-section than the fallopian tube. Optionally, an electric current is applied through the resilient structure to the fallopian tube, thereby effecting permanent sterilization.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 illustrates a first embodiment of a contraceptive intrafallopian device according to the present invention.

Fig. 2 illustrates a primary coil used in the contraceptive intrafallopian device of Fig. 1.

Fig. 3 illustrates a secondary coil which has been imposed on a primary coil as used in the contraceptive intrafallopian device of Fig. 1.

Fig. 4 illustrates a corewire for use with the contraceptive intrafallopian device of Fig. 1.

Fig. 5 is a cross-sectional view of a contraceptive delivery system having the contraceptive intrafallopian device of Fig. 1.

Fig. 6 illustrates an alternative embodiment of the present contraceptive intrafallopian device.

Fig. 7 illustrates a primary coil used in the contraceptive intrafallopian device of Fig. 6.

Fig. 8 schematically illustrates a contraceptive delivery system including the contraceptive intrafallopian device of Fig. 6.

Figs. 9 and 10 illustrates a method of delivery of a contraceptive intrafallopian device according to the present invention.

DETAILED DESCRIPTION OF THE SPECIFIC EMBODIMENT

The present invention encompasses a contraceptive intrafallopian device which can alternatively be used as both a permanent and a reversible means of contraception. The present contraceptive methods and devices minimize the danger of non-use which has limited the efficacy of prior art contraceptive techniques. Moreover, the location of the present devices within the fallopian tubes provides a reduced risk of the infectious complications, increased bleeding, and

pelvic pain associated with intrauterine devices (IUDs). The location and the novel shape of the present intrafallopian device provides significant advantages over IUDs, which have been found to be susceptible to unplanned expulsion and removal due to excessive pain and bleeding. The present invention takes advantage of the increase in effectiveness associated with copper IUDs, providing a resilient structure including copper which may be transcervically positioned without the need for surgery.

Although the present contraceptive method is included within a group of contraceptive techniques generally referred to as fallopian tube occlusion methods, the present invention does not necessarily rely solely on blocking the fallopian tube to prevent fertilization. Instead, contraception is apparently provided by disrupting of ovum transport, the process of fertilization, and/or cleavage of the ovum. While the effect that copper has on these processes is not fully understood, it does appear that copper intrafallopian devices offer potentially significant increases in effectiveness over intrafallopian devices formed of other materials. Optionally, the present invention further encompasses devices which promote the growth of tissue within the tube to induce tubal occlusion, further inhibiting conception.

Conveniently, the present resilient structures are adapted to be releasably affixed over a corewire, the corewire restraining the resilient structure in a straight configuration. As the resilient structure has an outer diameter when in the straight configuration which is less than the inner diameter of the fallopian tube, the catheter containing the present intrafallopian device is easily transcervically introduced.

The present invention is anchored within the isthmus of the fallopian tube, overcoming the unintended expulsion of the device and the resulting failure of the contraceptive method. Such intrafallopian device expulsion has been the single greatest factor limiting the efficacy of easily positioned intrafallopian contraceptive techniques. The

present intrafallopian devices are generally elongate resilient structures pre-formed into secondary shapes. These secondary shapes will preferably form anchors proximally and distally of the narrowest portion of the fallopian tube, called the isthmus. The secondary shape must have a larger outer diameter than the inner diameter of the isthmus.

The present device is generally readily removed by snaring the resilient structure near the proximal end and pulling proximally on the resilient structure, thereby straightening the resilient structure and allowing it to be withdrawn without injuring the fallopian tube. Alternatively, an electrical current is applied to the device after it is positioned within the fallopian tube, providing permanent sterilization.

Referring now to Fig. 1, a first embodiment of the present contraceptive intrafallopian device 10 is formed from a resilient primary coil 12. Primary coil 12 has a proximal end 14 and a distal end 16, the latter having an atraumatic endcap 18. Primary coil 12 further includes three portions: a proximal anchor portion 20, a distal anchor portion 22, and a lumen-traversing region 24. Proximal and distal anchors 20,22 are biased to form anchoring loops 26, as described hereinbelow.

Lumen-traversing region 24 comprises a substantially straight portion of primary coil 12. A ribbon 28 is wound over the outer surface of primary coil 12 to provide a helical shape. Ribbon 28 includes sharp outer edges 29, which firmly anchor lumen-traversing region 24 in the fallopian tube wall when torque is applied to intrafallopian device 10. The ribbon is preferably formed of a high strength biocompatible metal, ideally being stainless steel. The ribbon is attached to primary coil 12 at a proximal joint 30 and a distal joint 32, which may be formed of solder, heat-shrink tubing, or the like.

Referring now to Fig. 2, primary coil 12 is most easily formed in a straight configuration as a cylindrical coil or spring, preferably having an outer diameter in the range from .005 inch to .05 inch, and having a length in the

range from 20 mm to 150 mm. Ideally, primary coil 12 has an outer diameter in the range from .01 inch to .05 inch and a length in the range from 30 mm to 125 mm.

Preferably, primary coil 12 is formed from a beryllium copper alloy wire. Beryllium copper provides the resilience necessary to avoid expulsion of the device, and also provides the increased effectiveness of a copper contraceptive intrafallopian device. Such a beryllium copper wire will typically have a diameter from .002 inch to .01 inch. To provide the increased efficacy of a copper intrafallopian device, primary coil 12 preferably comprises an alloy including 75% copper. Alternatively, primary coil 12 is formed from a resilient metal, such as stainless steel, platinum, a shape memory alloy, or the like. If such materials are used, primary coil 12 is preferably plated with copper or a copper alloy or otherwise has copper attached.

Primary coil 12 includes a body winding 42 and a thread winding 44. Body winding 42 is formed with the minimum possible pitch to increase the stiffness of primary coil 12. Thread winding 44 will typically comprise from 0.1 cm to 2 cm adjacent to proximal end 14, and will have a pitch roughly twice that of body winding 42.

Referring now to Fig. 3, the proximal and distal anchors are formed by imposing a bent secondary shape on selected portions of primary coil 12. The secondary shape preferably comprises loops 26 formed by bending primary coil 12, and heat treating the primary coil while it is bent. A wide variety of secondary shapes may be used, including sinusoidal curves, alternating loops, or loops separated by straight sections so as to form a "flower coil," as more fully described in copending U.S. Patent Application Serial No. 08/424,777 ~~(Attorney Docket No. 16355-24)~~ the full disclosure of which is herein incorporated by reference. In all cases, the bent secondary shape should have an outer cross-section 46 which is larger than the fallopian tube to provide effective anchoring.

Referring now to Fig. 4, a corewire 50 for use with intrafallopian device 10 (Fig. 1) comprises a resilient wire

52 which tapers towards a distal end 54. Wire 52 is sufficiently stiff to restrain intrafallopian device 10 in a straight configuration, typically comprising stainless steel, platinum, or the like. A short section of coil forms corewire threads 56 attached at threadjoint 58. Threads 56 match the windings and pitch of threadwindings 44 of primary coil 12.

Referring now to Fig. 5, an intrafallopian contraceptive system 60 comprises corewire 50 inserted within a lumen 62 through intrafallopian device 10. Intrafallopian device 10 is releasably attached by engaging thread windings 44 with threads 56. Thus, intrafallopian device 10 is disengaged by torquing a proximal end of corewire 50 once intrafallopian device 10 is in position.

Referring now to Fig. 6, an alternative embodiment of the present intrafallopian device is again formed from a resilient primary coil 112 having a proximal end 114 and a distal end 116. The former includes a friction fitting 115. Primary coil 112 again includes three portions: a proximal anchor portion 120, a distal anchor portion 122, and a lumen-traversing region 124. Proximal and distal anchors 120, 122 are here biased to form opposed anchoring loops 26, thereby increasing the relaxed overall cross-section of the proximal and distal anchors. A ribbon 128 is wound over the outer surface of primary coil 112 to provide a helical shape, as described above.

Referring now to Fig. 7, primary coil 112 comprises a uniform body winding 142. The secondary shape is imposed on the straight cylindrical coil as opposed loops 126, or alternatively as multiple loops of a flower coil.

Referring now to Fig. 8, an intrafallopian contraceptive system using alternative intrafallopian device 100 includes a corewire 152 which tapers towards a distal end 154. Friction fitting 115 fittingly engages corewire 152, which restrains primary coil 112 in a straight configuration. A release catheter 164 is slidably disposed over corewire 152 proximally of alternative intrafallopian device 100, allowing the device to be released by withdrawing corewire 152 relative to the release catheter.

Use of the present contraceptive intrafallopian device will be described with reference to Figs. 9 and 10. A uterine introducer canula 70 is inserted transcervically through a uterus 72 to the region of an ostium 74. Alternatively, a hysteroscope may be used in place of canula 70.

Intrafallopian contraceptive system 60 is advanced distally of introducer cannula 70 and manuevered through the fallopian tube, preferably until intrafallopian device 10 extends distally of the isthmus. Optionally, intrafallopian contraceptive system 60 is self-guided, with corewire 52 bent near distal end 54 to assist intraluminal manuevering. Alternatively, a guide wire and catheter are advanced into the fallopian tube first, and the guide wire is replaced with intrafallopian contraceptive system 60. In either case, the intrafallopian device is axially positioned with lumen-traversing region 24 within a target region 84 adjacent to isthmus 80. Preferably, at least one loop of distal anchor 22 is distal of target region 84, and at least one loop of proximal anchor 20 is proximal of target region 84 to form the distal and proximal anchor bends.

Once intrafallopian device 10 is properly positioned, corewire 50 is torqued to set ribbon 28 in the tubal wall. The corewire may then be unthreaded from intrafallopian device 10 by rotating the corewire in the opposite direction, disengaging threads 56 from thread windings 44. The corewire is then free to slide proximally, releasing the primary coil. As the distal end of the primary coil is released, a distal anchor bend 90 is formed. Similarly, a proximal loop forms a proximal anchor bend 92. The anchor bends help to axially restrain the device within the fallopian tube, and also prevent rotation around the helical shape of lumen-traversing region 24. As seen in Fig. 10, the loops need not assume their relaxed form to provide effective distal or proximal anchors.

The present invention further encompasses permanent sterilization by passing a current through the corewire to the intrafallopian device prior to withdrawing the corewire.

Fallopian tube tissue in contact with the intrafallopian device is dessechated, and thus attached to the present intrafallopian device. This action also causes permanent tubal damage, leading to the formation of scar tissue which encapsulates the intrafallopian device and causes permanent occlusion of the tubal lumen. Clearly, the corewire/primary coil interface must be conductive to allow the present non-surgical method of permanent sterilization.

In conclusion, the present invention provides a contraceptive intrafallopian device which may be positioned without surgery. While the above is a complete description of the preferred embodiments of the invention, various alternatives, modifications, and equivalents may be used. For example, a wide variety of secondary shapes, including open loops, continuous bends, sinusoidal curves, or the like, may be imposed on the primary coil. Therefore, the above description should not be taken as limiting the scope of the invention, which is defined instead solely by the appended claims.

WHAT IS CLAIMED IS:

1. An intrafallopian contraceptive device comprising:

a proximal anchor having a proximal cross-section;

a distal anchor having a distal cross-section; and

a lumen-traversing region extending between the proximal anchor and the distal anchor, the lumen traversing region having a helical outer surface and a helical cross-section which is smaller than both the proximal cross-section and the distal cross-section.

2. An intrafallopian contraceptive device as claimed in claim 1, wherein the lumen-traversing region comprises a resilient structure.

3. An intrafallopian contraceptive device as claimed in claim 2, wherein the lumen-traversing region further comprises a ribbon wound over the outer surface of the resilient structure.

4. An intrafallopian contraceptive device as claimed in claim 2, wherein the ribbon includes a sharp outer edge.

5. An intrafallopian contraceptive device as claimed in claim 1 wherein at least one of the proximal anchor, the distal anchor, and the lumen-traversing region comprises copper.

6. An intrafallopian contraceptive device as claimed in claim 1 wherein at least one of the proximal anchor and the distal anchor comprises a resilient structure biased to form a secondary shape.

7. An intrafallopian contraceptive device as claimed in claim 6, wherein the resilient structure comprises a primary coil.

8. An intrafallopian contraceptive device as claimed in claim 7, wherein the primary coil comprises a material selected from the group consisting of beryllium, stainless steel, platinum, and shape memory alloy.

9. An intrafallopian contraceptive device as claimed in claim 8, wherein the primary coil comprises an alloy including beryllium and copper.

10. An intrafallopian device as claimed in claim 7, wherein the primary coil comprises an alloy including at least 75% copper.

11. An intrafallopian contraceptive device as claimed in claim 1, wherein a lumen extends from a proximal end of the proximal anchor to near a distal end of the distal anchor.

12. An intrafallopian contraceptive device comprising:

a primary coil having a distal loop, a proximal loop, and an intermediate straight section between the distal loop and the proximal loop; and

a helical ribbon wound over at least a portion of the intermediate section.

13. An intrafallopian contraceptive device as claimed in claim 12, wherein the ribbon has a width in the range between .005 and .1 inch.

14. An intrafallopian contraceptive device as claimed in claim 13, wherein the ribbon has a thickness in the range between .001 and .2 inch.

15. An intrafallopian contraceptive device as claimed in claim 12, wherein the ribbon has a pitch in the range between .01 and .2 inch.

16. An intrafallopian contraceptive device as claimed in claim 12, wherein the device has a length in the range between 1.5 cm and 7.5 cm when in a relaxed state.

17. An intrafallopian contraceptive device as claimed in claim 12, wherein the device comprises copper.

18. An intrafallopian contraceptive device as claimed in claim 17, wherein the primary coil comprises a material selected from the group consisting of beryllium, stainless steel, platinum, and shape memory alloy.

19. An intrafallopian contraceptive device as claimed in claim 18, wherein the primary coil comprises an alloy including beryllium and copper.

20. An intrafallopian contraceptive device as claimed in claim 12, wherein the primary coil includes a lumen which extends from a proximal end of the proximal loop to near the distal end of the distal loop.

21. An intrafallopian contraceptive device as claimed in claim 12, wherein the primary coil has an outer diameter in the range between .2 mm and 5 mm.

22. An intrafallopian contraceptive device as claimed in claim 12, wherein the distal loop and the proximal loop have outer diameters of at least 3 mm when in a relaxed state.

23. An intrafallopian contraceptive system comprising:

a primary coil having a distal loop, a proximal loop, an intermediate straight section between the distal loop and the proximal loop, and a lumen from a proximal end of the proximal loop to near a distal end of the distal loop;

a helical ribbon wound over at least a portion of the intermediate section; and

a corewire removably disposed within the lumen of the primary coil, the corewire restraining the primary coil in a straight configuration.

24. An intrafallopian contraceptive system as claimed in claim 23, wherein the primary coil comprises copper.

25. An intrafallopian contraceptive system as claimed in claim 23, wherein the corewire is threadably received by the primary coil.

26. An intrafallopian contraceptive system as claimed in claim 23, further comprising a release catheter slidably disposed over the corewire proximally of the primary coil, the release catheter having a distal primary coil engaging surface for restraining the primary coil while the corewire is withdrawn proximally.

27. An intrafallopian contraceptive method comprising:

restraining a resilient structure in a straight configuration over a corewire, the resilient structure including a lumen-traversing region having a helical outer surface;

transcervically introducing the resilient structure into a target region of a fallopian tube; and

withdrawing the corewire from the resilient structure to mechanically anchor the resilient structure within the fallopian tube, at least a portion of the resilient structure assuming a secondary shape which is larger in cross-section than the fallopian tube.

28. A method as claimed in claim 27, wherein the target region is adjacent to an ostium of the fallopian tube.

29. A method as claimed in claim 28, wherein the target region extends distally of an isthmus of the fallopian tube.

30. A method as claimed in claim 27, further comprising torquing the corewire to anchor the resilient structure, the helical shape having a sharp outer edge.

31. A method as claimed in claim 27, wherein the withdrawing step comprises forming a distal anchor from a portion of the resilient structure which is distal of the lumen-traversing region, and forming a proximal anchor from a portion of the resilient structure which is proximal of the lumen-traversing region, the distal portion and the proximal portion assuming the secondary shape.

32. A method as claimed in claim 27, wherein the withdrawing step comprises unthreading the corewire from the resilient structure.

33. A method as claimed in claim 27, wherein the withdrawing step comprises axially restraining the resilient structure with a release catheter, the release catheter being slidably disposed over the corewire proximally of the resilient structure.

34. A method as claimed in claim 27, further comprising applying an electrical current through the resilient structure to the fallopian tube to permanently prevent conception.

35. An intrafallopian sterilization method comprising:

transcervically introducing a structure into a target region of a fallopian tube, the structure being releasably attached to a distal end of an elongate body;

applying an electrical current through the elongate body to the structure, and through the structure to the fallopian tube to permanently anchor the structure within the fallopian tube; and

releasing the structure from the elongate body and withdrawing the elongate body.

Add 87

CONTRACEPTIVE TRANSCERVICAL FALLOPIAN TUBE OCCLUSION DEVICES HAVING MECHANICAL FALLOPIAN TUBE ATTACHMENT

ABSTRACT OF THE DISCLOSURE

The invention provides intrafallopian devices and non-surgical methods for their placement to prevent conception. The efficacy of the device is enhanced by forming the structure at least in part from copper or a copper alloy. The device is anchored within the fallopian tube by a lumen-traversing region of the resilient structure which has a helical outer surface, together with a portion of the resilient structure which is biased to form a bent secondary shape, the secondary shape having a larger cross-section than the fallopian tube. The resilient structure is restrained in a straight configuration and transcervically inserted within the fallopian tube, where it is released. Optionally, permanent sterilization is effected by passing a current through the resilient structure to the tubal walls.

A y Docket No. 16355-002500

DECLARATION

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **CONTRACEPTIVE TRANSCERVICAL FALLOPIAN TUBE OCCLUSION DEVICES HAVING MECHANICAL FALLOPIAN TUBE ATTACHMENT** the specification of which _X_ is attached hereto or ___ was filed on _____ as Application Serial No. _____ and was amended on ___ (if applicable).

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign applications(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119
			Yes ___ No ___
			Yes ___ No ___

I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Date of Filing	Status
		___ Patented ___ Pending ___ Abandoned
		___ Patented ___ Pending ___ Abandoned

Full Name of Inventor 1	Last Name **NIKOLCHEV**	First Name **JULIAN**	Middle Name or Initial	
Residence & Citizenship	City **Portola Valley**	State/Foreign Country **California** CA	Country of Citizenship **United States of America**	
Post Office Address	Post Office Address **251 Durazno Way**	City **Portola Valley**	State/Country **California**	Zip Code **94028**
Full Name of Inventor 2	Last Name **TON**	First Name **DAI**	Middle Name or Initial	
Residence & Citizenship	City **San Jose**	State/Foreign Country **California** CA	Country of Citizenship **United States of America**	
Post Office Address	Post Office Address **1693 Flickinger Avenue**	City **San Jose**	State/Country **California**	Zip Code **95131**
Full Name of Inventor 3	Last Name ///	First Name	Middle Name or Initial	
Residence & Citizenship	City	State/Foreign Country	Country of Citizenship	
Post Office Address	Post Office Address	City	State/Country	Zip Code

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1	Signature of Inventor 2	Signature of Inventor 3
JULIAN NIKOLCHEV	**DAI TON**	///
Date 6/7/95	Date 6/7/95	Date

ty. Docket No. 16355-002500

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(c)) - SMALL BUSINESS CONCERN

Applicant or Patentee: JULIAN NIKOLCHEV and DAI TON
Serial or Patent No.:
Filed or Issued:
Title: CONTRACEPTIVE TRANSCERVICAL FALLOPIAN TUBE OCCLUSION DEVICES HAVING MECHANICAL FALLOPIAN TUBE ATTACHMENT

I hereby declare that I am,

[ ] the owner of the small business concern identified below:

[X] an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN CONCEPTUS, INC.
ADDRESS OF SMALL BUSINESS CONCERN 1021 Howard Avenue, San Carlos, California 95131

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled CONTRACEPTIVE TRANSCERVICAL FALLOPIAN TUBE OCCLUSION DEVICES HAVING MECHANICAL FALLOPIAN TUBE ATTACHMENT by inventor(s) JULIAN NIKOLCHEV and DAI TON described in

[X] the specification filed herewith
[ ] application Serial No. _____, filed _____
[ ] Patent No. _____, issued _____

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights in the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern that would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME
ADDRESS

[ ] INDIVIDUAL [ ] SMALL BUSINESS CONCERN [ ] NONPROFIT ORGANIZATION

NAME
ADDRESS

[ ] INDIVIDUAL [ ] SMALL BUSINESS CONCERN [ ] NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Julian Nikolchev
TITLE OF PERSON IF OTHER THAN OWNER VP
ADDRESS OF PERSON SIGNING 1021 Howard Avenue, San Carlos, California 94070

SIGNATURE _____ DATE 6/7/95

[illegible]

16 15-25
SHT 1 OF 5

08/475252

5-1
330



FIG_2



FIG_3



FIG_1

FIG_4



FIG_5



FIG_8



FIG_7





FIG_6

6355-25
SHT 4 OF 5

08/475252

FIG-9





FIG-10



FIG_2



FIG_3



FIG_1

PRINT OF DRAWINGS AS ORIGINALLY FILED

16355-25
SHT 2 OF 5

08/475252



FIG-4



FIG-5



FIG-8

PRINT OF DRAWINGS
AS ORIGINALLY FILED

6355-25
SHT 3 OF 5

08/475252

FIG-7





FIG-6

PRINT OF DRAWINGS
AS ORIGINALLY F

16355-25
SHT 5 OF 5

08/475252



FIG-10

16355-25
SH 4 OF 5



FIG-9